503 related articles for article (PubMed ID: 15148813)
1. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
[TBL] [Abstract][Full Text] [Related]
2. [Neural crest and multiple endocrinopathies].
Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M
C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721
[TBL] [Abstract][Full Text] [Related]
3. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
4. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
Frank-Raue K; Rondot S; Schulze E; Raue F
Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
[TBL] [Abstract][Full Text] [Related]
5. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2).
Jimenez C; Gagel RF
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S150-7. PubMed ID: 15135800
[TBL] [Abstract][Full Text] [Related]
6. Double germline mutations in the RET Proto-oncogene in MEN 2A and MEN 2B kindreds.
Dvorakova S; Vaclavikova E; Ryska A; Cap J; Vlcek P; Duskova J; Kodetova D; Holub V; Novak Z; Bendlova B
Exp Clin Endocrinol Diabetes; 2006 Apr; 114(4):192-6. PubMed ID: 16705552
[TBL] [Abstract][Full Text] [Related]
7. [Multiple endocrine neoplasia type 2A, type 2B and familial medullary thyroid carcinoma syndrome].
Obara T; Yamashita T; Kanbe M; Ito Y; Egawa S; Yamaguchi K
Nihon Rinsho; 1995 Nov; 53(11):2708-15. PubMed ID: 8538031
[TBL] [Abstract][Full Text] [Related]
8. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
[TBL] [Abstract][Full Text] [Related]
9. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB
Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527
[TBL] [Abstract][Full Text] [Related]
10. Clinical manifestations of familial medullary thyroid carcinoma.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):348-50. PubMed ID: 15271414
[TBL] [Abstract][Full Text] [Related]
11. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
12. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
[TBL] [Abstract][Full Text] [Related]
13. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
14. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.
Jindrichová S; Vcelák J; Vlcek P; Neradilová M; Nemec J; Bendlová B
J Endocrinol; 2004 Nov; 183(2):257-65. PubMed ID: 15531714
[TBL] [Abstract][Full Text] [Related]
15. RET oncogene mutations in medullary thyroid carcinoma in Mexican families.
González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B
Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374
[TBL] [Abstract][Full Text] [Related]
16. Efficient testing of the RET gene by DHPLC analysis for MEN 2 syndrome in a cohort of patients.
Pazaitou-Panayiotou K; Kaprara A; Sarika L; Zovoilis T; Belogianni I; Vainas I; Nasioulas G
Anticancer Res; 2005; 25(3B):2091-5. PubMed ID: 16158949
[TBL] [Abstract][Full Text] [Related]
17. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
[TBL] [Abstract][Full Text] [Related]
18. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
19. RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A.
Chung YJ; Kim HH; Kim HJ; Min YK; Lee MS; Lee MK; Kim KW; Ki CS; Kim JW; Chung JH
Thyroid; 2004 Oct; 14(10):813-8. PubMed ID: 15588376
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
